The Potential Value of Minimal Disease Activity in Atopic Dermatitis

Abstract

Keywords

atopic dermatitis treat-to-target cumulative life course impairment minimal disease activity T2T CLCI MDA

Get full access to this article

View all access options for this article.

References

Laughter

Maymone

MBC

Mashayekhi

, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017. Br J Dermatol. 2021;184:304-309. doi:10.1111/bjd.19580

Silverberg

Gooderham

Katoh

, et al. 327 Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy. Br J Dermatol. 2023;188:ljac140.022. doi:10.1093/bjd/ljac140.022

Kimball

Gieler

Linder

Sampogna

Warren

Augustin

. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol. 2010;24:989-1004. doi:10.1111/j.1468-3083.2010.03705.x

Silverberg

Gooderham

Katoh

, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38:2139-2148. doi:10.1111/jdv.20229

Zardin-Moraes

da Silva

ALFA

Saldanha

, et al. Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis. J Rheumatol. 2020;47:839-846. doi:10.3899/jrheum.190677